Study finds women are 2-3 times more likely to be affected than men Women in low- and middle-income countries, especially in the Sub-Saharan Africa region, may be 10 times more likely to have obesity or heart health issues than their male counterparts, according to a large meta-analysis published in The Journal of Clinical Endocrinology and Metabolism....
The Endocrine Society continues to be a vocal advocate to advance legislation that would address prevention and treatment of obesity. In late July, legislation known as the Treat and Reduce Obesity Act (TROA) that the Society endorsed was introduced in the House and the Senate. This important bipartisan legislation would take steps to ensure that...
Obesity appears to increase the risk of developing polycystic ovary syndrome (PCOS), according to a study presented at ENDO 2023. An estimated 7% to 10% of all reproductive-aged women globally have PCOS. Women with PCOS have a hormonal imbalance and metabolism problems that may affect their overall health, appearance, and fertility. PCOS is associated with health...
Researchers at McMaster University have uncovered a key mechanism for promoting weight loss and maintaining the burning of calories during dieting, according to a paper published recently in Nature. Researchers led by Gregory R. Steinberg, PhD, a professor of the Department of Medicine at McMaster University and co-director of the Centre for Metabolism, Obesity, and...
People who have just one or two drinks per day are not protected against endocrine conditions such as obesity and type 2 diabetes, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism. Alcohol consumption is a significant public health concern because it is related to many medical conditions such as...
People with obesity may have lower work productivity due to increased risk of illness, contributing to increased costs for employers, according to industry-supported research being presented Saturday at ENDO 2023, the Endocrine Society’s annual meeting, in Chicago, Ill. Obesity is a significant public health issue affecting approximately 42% of people in the United States. Employees...
Tirzepatide – the dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) injection used to treat type 2 diabetes – is safe and has a tolerable adverse event (AE) profile in its role in the management of T2D, and possibly obesity, according to a study recently published in the Journal of the...
Weight loss achieved through the use of a combination of anti-obesity medications (AOMs) can approach the reduction seen in bariatric surgery, according to a paper recently published in JCEM Case Reports. Researchers led by Priya N. Patel, MD, of the Center for Pediatric Obesity Medicine at the University of Minnesota Medical School in Minneapolis point...
Tirzepatide – the dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) injection used to treat type 2 diabetes – is safe and has a tolerable adverse event (AE) profile in its role in the management of T2D, and possibly obesity, according to a study recently published in the Journal of the...
